← Back to blog

Clinical Operations Metrics: What to Track and Why

November 5, 2026
Clinical Operations Metrics: What to Track and Why

Clinical operations metrics are the process measures that show whether a trial is moving at the pace and quality your milestones need: startup time, site activation, enrollment, retention, query turnaround, protocol deviations and closeout speed. Outcome measures tell you whether the drug works. Operational metrics tell you whether the trial will finish on time and whether its data will hold up. The useful set is small, tied to a milestone, and read next to quality signals.

Haiphai
haiphai.com
Reduce Delays in Clinical Operations
HaiPhai works with life sciences teams to identify bottlenecks and apply AI to processes such as regulatory drafting and clinical site activation.
Visit HaiPhai

TL;DR

  • Track metrics along the trial timeline: startup, site activation, enrollment and retention, site management, data and safety, closeout.
  • A metric becomes a KPI only when it is tied to a target, such as a milestone date or randomization pace.
  • Benchmarks only compare if definitions match, and phase, therapeutic area and biomarker selection change the numbers.
  • Read speed metrics beside quality signals like protocol deviations, late safety reporting and data anomalies.
  • Report to executives and investors as milestone risk, not as a long list of numbers.

Table of Contents

What clinical operations metrics are, and what they are not

A clinical trial has two kinds of numbers. The first kind is the endpoint: in the FDA's estimand framework, a variable of interest such as death, a total score or time to progressive disease, summarized at the population level. That is the science.

The second kind is operational: how long it took to get the first site live, how many screened patients were randomized, how fast queries close. These do not say whether the therapy works. They say whether you will learn the answer on schedule.

Pfizer's quality-metrics framework is a clean way to see the relationship. It separates outcome metrics (was the required quality standard achieved), predictor metrics (are we progressing toward it) and contributor metrics, which are process-related operational measures expected to contribute to quality. Most of what clinical operations tracks sits in that third group. That is why a scoreboard of cycle times means little unless it is linked to a quality risk.

Metric versus KPI

Not every measurement deserves a dashboard tile. Clinical Leader makes the point that a KPI is a metric measured against an organizational goal or target. In practice, "median days to site activation" is a metric. "Fifteen sites active by the end of the quarter, so that last-patient-in lands in the planned window" is a KPI.

The metrics worth tracking, phase by phase

The list below is built from published ClinOps frameworks and site-performance guides, organized the way a trial unfolds. Pick a few per stage rather than all of them.

StageMetricsWhat it tells you
StartupFinal protocol to first site activated; contract cycle time; budget finalization time; protocol submission to IRB approvalWhether the paper work is gating the clinic work
Site activationProtocol final to first-patient-in; IRB approval to first patient first visitHow fast a site goes from selected to productive
Recruitment and retentionScreen-to-randomization ratio; screen failure rate; enrollment per site per month; dropout; lost to follow-upWhether the enrollment plan is realistic
Site managementQuery turnaround; deviations per participant; eTMF completenessWhether sites are running the protocol cleanly
Data and safetySAE reporting time; visit-to-EDC entry timeWhether data is timely and safety is visible
CloseoutLast subject last visit to database lockHow quickly data becomes a readout

The startup, recruitment, site management, data and closeout groupings follow a ClinOps guide that lists exactly these measures. A clinical trial performance metrics overview adds protocol submission to IRB approval, budget-finalization time, query-resolution time, screening-to-enrollment ratio, retention and protocol deviations.

Site-side metrics sponsors often forget

Sites run on people. The Society for Clinical Research Sites toolkit lists Time to Onboard and CRC Workload as HR indicators: time from hire acceptance to operational readiness, and studies, patients or visits per coordinator. If your best-enrolling site is quietly overloaded, its numbers will slip before anyone asks why. Site financial indicators matter as well: the same organization has categorized common site KPIs such as aging accounts receivable and revenue per coordinator. Late payment is a startup and retention risk, and our piece on site payment delays looks at it in detail.

How the key metrics are calculated

Definitions differ between sponsors, CROs and sites, so write yours down before you compare anything. These are the working definitions we use as a starting point.

  • Site activation time: days from a fixed start event to the date the site is cleared to enroll. Choose the start event (final protocol, site selection, or contract package sent) and keep it constant. Many teams use final protocol to first site activated, plus the median across all sites.
  • Study startup time: days from final protocol to first patient in. It is the sum of several steps (contract, budget, IRB, training, supplies), so track the steps too.
  • Enrollment rate: randomized or enrolled patients divided by the number of active site-months. Count a site only from its activation date, or sites that opened late will make the rate look worse than it is.
  • Screen failure rate: patients screened but not randomized, divided by patients screened. Split by reason, because an eligibility problem and a consent problem need different fixes.
  • Retention: patients still in the study at a defined visit, divided by patients randomized. Report dropout and lost to follow-up separately.
  • Protocol deviations: count per participant or per hundred visits, split into important and minor. Raw counts mislead because larger sites always have more.
  • Query turnaround: median days from query issued to query closed, reported by site.

One rule from the trade press is worth keeping: external benchmarking needs standardized, consistently measured definitions, and negative or outlier cycle times should be checked, because they usually come from data entry errors rather than miracles.

Benchmarks: useful, but only if you compare like with like

Published numbers are anchors, not targets. Take oncology. One U.S. oncology research group reports a median enrollment of 1.8 patients per site per month, 38% average screen failure, a 14.2-week median site startup and 84% retention, and notes that results shift with biomarker complexity and line of treatment. In biomarker-selected colorectal studies the same source gives an average of 1.2 patients per site per month. Applying the broad oncology figure to a narrow biomarker trial would flag a healthy program as failing.

Benchmarks: useful, but only if you compare like with like

Older U.S. startup data still shows where time hides. A site-metrics presentation prepared for the Clinical Trials Transformation Initiative reports a median of 80 days between IRB final decision and first patient first visit, with central IRB sites approving 27 days sooner and enrolling their first subject 21 days sooner than local IRB sites. The same material links early recruitment to success: a first subject consented within 30 days corresponds to a 90%+ chance of success, falling to under 10% at 90 days. The data is from 2009 to 2010, so treat it as direction rather than a current norm. The lesson holds: the first weeks after activation predict a lot.

Rules for using a benchmark

  1. Match phase, therapeutic area and population complexity.
  2. Match the definition, including the start and end events.
  3. Use medians, not averages, because a few slow sites skew averages.
  4. Compare against your own earlier trials first. They share your contracts, your IRB mix and your vendors.

Read speed beside quality

Fast is only good if the data is clean. Current FDA expectations for monitoring support centralized review and targeted onsite visits, using site-level signals such as protocol deviation patterns, delayed safety reporting and data anomalies to decide where to look. The practical implication: a site that enrolls quickly but shows rising deviations is a risk, not a star.

The CTTI and FDA quality-by-design pilot names patient safety, data integrity and protocol compliance as common quality objectives, and lists quality metrics such as randomized subjects who do not meet inclusion or exclusion criteria and the percentage with inadequate informed consent. Pair each speed metric with a quality counterpart:

Speed metricQuality counterpart
Enrollment per site per monthEligibility errors, consent errors
Visit-to-EDC entry timeData anomalies, query rate
Site activation timeTraining completeness, eTMF completeness
Database lock timeOpen queries and unreconciled safety data

For teams working with molecular data, this idea of reading operational measures with quality signals also appears in discussions of data reporting in molecular biology. If you are setting up the monitoring side, our 90-day risk-based monitoring checklist walks through it, and the guide to protocol deviation reduction covers the deviation metric in depth.

From metrics to decisions

Goldfarb's guidance for sites is that a metric should be actionable: it should point the way to doing something better, as described in his site-performance article. Use that as a filter. For each metric, write down who owns it, what number triggers action and what the action is. If you cannot, drop the metric.

A simple review rhythm

  • Weekly: activation status by site, screening and randomization counts, open queries, late SAE reports.
  • Monthly: medians and trends against plan, deviations per participant, site workload, payment status.
  • Quarterly: metric definitions, targets and whether any metric has stopped driving decisions.

Share the numbers with sites

A 2026 Cambridge University Press appraisal of sponsor and site interactions suggests operational metrics should be used in both directions, with infrastructure, workforce and trial funnel as the three pillars of metric-driven collaboration. Sites that see how they compare, and what the sponsor is doing about shared delays such as contracts and payments, tend to be easier to work with. A site readiness conversation early on helps too, and our site readiness checklist is built for it.

Reporting to executives and investors

Leadership does not need forty metrics. They need to know which milestone is at risk, by how much, and what is being done. A good page has four elements: the milestone and its date, the leading indicator that predicts it (sites activated, randomization pace), the main driver of any slip, and the decision requested. Keep detail one click away. Our notes on audit-ready clinical trial dashboards cover how to keep every number traceable to its source, and the site performance analytics guide outlines a compact KPI set.

Four fields in an executive trial report

Where the delay usually sits

In our experience, the biggest gaps are not in the metrics themselves but in the handoffs between them. Contract negotiation waits on budget, budget waits on protocol clarity, IRB review waits on a complete package. Measuring each step separately shows which one is gating the others. Work done in parallel instead of in sequence is the usual lever, and we explain how in our pieces on clinical site activation bottlenecks and the site activation process. Linking critical-to-quality factors to owners and KPIs, covered in clinical protocol governance, keeps those numbers from drifting apart from the protocol.

Perspective

Most biotech teams we meet are not short of data. They are short of a line between a number and a decision. A dashboard that shows 14 weeks to activation is a report. A dashboard that shows which of the five steps inside those 14 weeks is slipping, who owns it and what it does to the financing milestone is an operating tool.

That is why we start from your strategic goals and work backward. If the goal is a first-patient-in date that supports your next raise, we map the path to it, find the bottlenecks in regulatory drafting, contracting and site activation, and then decide where AI belongs. Sometimes it is drafting. Sometimes it is institutional knowledge that never made it into a system. Sometimes it is governance, so that automation stays inside the rules your quality team can defend.

We embed senior experts in your live operations because metrics only improve when someone redesigns the workflow around them and stays to see it adopted. Our aim is to help teams reclaim months of operational time on the path to approval, and operational metrics are how you see that progress.

John

How HaiPhai can help

If your metrics show startup or regulatory work running longer than your milestones allow, we can start with an AI Velocity Diagnostic that maps where the time goes, then redesign those workflows with you and stay on to govern them. Our work spans clinical, scientific and regulatory operations, institutional knowledge, executive operations and governed automation.

Haiphai

Learn how an embedded operating partnership works, or start from haiphai.com to see where it fits your pipeline.

FAQ

What are the most important clinical operations metrics for a small biotech?

Start with final protocol to first site activated, enrollment per active site-month, screen failure rate, deviations per participant, query turnaround and last subject last visit to database lock. They cover speed and quality across the trial and map directly to financing and readout milestones.

What is the difference between a metric and a KPI in clinical operations?

A metric is any measurement. A KPI is a metric tied to a goal or target, such as a milestone delivery date or a randomization pace. If a number has no target and no owner, it is a metric only.

Can I compare my trial to published benchmarks?

Yes, if phase, therapeutic area, population and metric definitions match. Oncology figures, for example, change with biomarker selection and line of treatment, so a broad median can misrepresent a narrow study. Your own prior trials are usually the best comparison.

How do I track speed without losing quality?

Pair every speed metric with a quality signal, such as deviation patterns, delayed safety reporting or data anomalies, and use those signals to target monitoring where the risk is highest, in line with FDA's risk-based monitoring guidance.

Sources